Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Yoshimura, Kazuki  [Clear All Filters]
2023
Nakamura Y, Kawamura S, Matsumi S, Matsumoto K, Tanaka S, Ishikawa T, Matsuoka A, Meno T, Kawamura M, Takeshita J, et al. [Anti-MDA5 antibody-positive rapidly progressive interstitial lung disease after allogeneic hematopoietic cell transplantation successfully treated with triple immunosuppressive therapy]. Rinsho Ketsueki. 2023;64(4):250-254.
Yoshino N, Kimura S-I, Matsuoka A, Meno T, Ishikawa T, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Misaki Y, et al. Clinical features of febrile neutropenia and bloodstream infection in autologous hematopoietic cell transplantation: Comparison to those in intensive chemotherapy for acute myeloid leukemia. J Infect Chemother. 2023.
Kusuda M, Nakasone H, Yoshimura K, Okada Y, Tamaki M, Matsuoka A, Ishikawa T, Meno T, Nakamura Y, Kawamura M, et al. Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients. Br J Haematol. 2023.
Matsumi S, Kimura S-I, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, et al. Substitution of calcineurin inhibitors with corticosteroids after allogeneic hematopoietic cell transplantation. Int J Hematol. 2023.
2022
Kawamura S, Tamaki M, Nakamura Y, Kawamura M, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, Gomyo A, et al. Successful treatment of the TEMPI syndrome with pomalidomide plus dexamethasone followed by autologous stem cell transplantation. Acta Haematol. 2022.
2021
Takeshita J, Kimura S-I, Nakasone H, Kawamura S, Nakamura Y, Kawamura M, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, et al. Association between the kinetics of cytomegalovirus reactivation in terms of the area under the curve of cytomegalovirus antigenemia and non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2021.
Kawamura S, Nakasone H, Takeshita J, Kimura S-I, Nakamura Y, Kawamura M, Misaki NYoshinoYuk, Yoshimura K, Matsumi S, Gomyo A, et al. Prediction of CMV reactivation by recipient CMV-IgG titer before allo-HCT. Transplant Cell Ther. 2021.
2020
Kimura S-I, Takeshita J, Kawamura M, Kawamura S, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, Gomyo A, Akahoshi Y, et al. Association between the kinetics of cytomegalovirus reactivation evaluated in terms of the area under the curve of cytomegalovirus antigenemia and invasive mold infection during the post-engraftment phase after allogeneic hematopoietic stem cell transplan. Transpl Infect Dis. 2020:e13387.
Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, et al. Detection of T315I using digital PCR in allogeneic transplant recipients with Ph-positive ALL in the dasatinib era. Exp Hematol. 2020.
Kimura S-I, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, Gomyo A, et al. Impact of neutropenia evaluated in terms of the D-index on invasive fungal disease while on empiric or preemptive antifungal treatment strategy in the early phase after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2020:e13409.
2019
Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, et al. Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT. Blood Adv. 2019;3(21):3287-3296.
Kimura S-I, Sato M, Misaki Y, Yoshimura K, Gomyo A, Hayakawa J, Akahoshi Y, Harada N, Tamaki M, Kusuda M, et al. Prospective validation of the L-index reflecting both the intensity and duration of lymphopenia and its detailed evaluation using a lymphocyte subset analysis after allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2019:101262.
Ashizawa M, Akahoshi Y, Nakano H, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, Tamaki M, et al. Updated clinical outcomes of hematopoietic stem cell transplantation using myeloablative total body irradiation with ovarian shielding to preserve fertility. Biol Blood Marrow Transplant. 2019.